Safety Comparison – Phototherapy vs Biologics

Compare the Safety of Ultraviolet Phototherapy vs. Biological Drugs Used for the Treatment of Skin Disease

While biological drug therapies have become popular in the last few years, it is important to evaluate the safety of these medications. Every one of the following drugs has had numerous adverse effects and deaths where the drug was listed as the primary suspected cause. In contrast, Daavlin’s phototherapy is an extremely safe and effective method of treatment. Even Oxsoralen, a drug used in conjunction with ultraviolet light to create PUVA, has an exemplary safety record. We invite you to view the statistics of our competitors. Click the links to read FDA statements and other related information.

Adverse Effects:

Primary Suspect Adverse Effects for 2006-2020 Deaths for 2006-2020
Oxsoralen® 17 3
Cosentyx® 33,884 1,269
Protopic® 22,773 2,476
Elidel® 828 57
Raptiva® 869 312
Otezla® 18,244 1,161
Methotrexate 70,857 5,014
Stelara® 35,482 1,347
Humira® 219,414 18,747
Remicade® 99,037 6,996
Enbrel® 133,665 9,361
Skyrizi® 2,097 136
Tremfya® 2,150 96
Taltz ™ 2,372 176
Simponi® 18,824 547
Cimzia® 28,166 862
Xeljanz® 38,548 2,308

To view detailed information from the chart above, click here.

*Although appearing to be the most innocuous of the biologic drugs in the comparison above; Raptiva was removed from the U.S. market on April 8, 2009 due to the risk of PML, a fatal brain infection. Data compiled using MedWatch statistics available at Enbrel is a registered trademark of Amgen, Inc. / Wyeth Pharmaceuticals. Humira is a registered trademark of Abbott Laboratories. Remicade is a registered trademark of Centocor, Inc. Raptiva is a registered trademark of Genentech. Elidel is a registered trademark of Novartis. Protopic is a registered trademark of Astellas Pharma.